Uttarakhand health regulator asks Patanjali unit to stop production of Bpgrit, Madhugrit and 3 other medicines

Written by Ruchika Sharma Published On 2022-11-12T15:45:47+05:30 | Updated On 14 Nov 2022 6:58 AM GMT

Uttarakhand health regulator asks Patanjali unit to stop production of Bpgrit, Madhugrit and 3 other medicines

New Delhi: Dehradun, Uttarakhand Ayurveda, and Unani Licensing Authority has asked Divya Pharmacy to stop the production of five medicines and produce their revised formulation sheets for approval. Divya Pharmacy manufactures Yoga guru Ramdev's Patanjali products.According to the notice issued on Wednesday, Bpgrit, Madhugrit, Thyrogrit, Lipidom tablets, and Eyegrit Gold tablets are being...

New Delhi: Dehradun, Uttarakhand Ayurveda, and Unani Licensing Authority has asked Divya Pharmacy to stop the production of five medicines and produce their revised formulation sheets for approval. Divya Pharmacy manufactures Yoga guru Ramdev's Patanjali products.

According to the notice issued on Wednesday, Bpgrit, Madhugrit, Thyrogrit, Lipidom tablets, and Eyegrit Gold tablets are being promoted as medicines for blood pressure, diabetes, goitre, glaucoma, and high cholesterol.

The notice says the company can restart manufacturing these products only after the authority approves their revised formulation sheets.

A panel constituted by the authority has already examined the original formulation sheets and label claims of the products.

Read also: Patanjali moves to court supporting PIL seeking Holistic Integrated Medicinal System for medical education and treatment

The action was taken following a complaint filed by a doctor from Kerala, K V Babu, in which he had accused Divya Pharmacy of violating the Drugs and Magic Remedies (objectionable advertisement) Act and the Drugs and Cosmetic Act.

Babu had lodged his complaint against the firm with Uttarakhand Ayurveda and Unani Licensing Authority in July this year and followed it up with another via email on October 11.

The notice signed by the joint director and drug controller of the state health authority G C N Jangapangi has sought a reply from Divya Pharmacy within a week.

Read also: Indian Medicines Pharmaceutical Corp pays Rs 10 crore dividend to stakeholders

It has also asked the firm to remove all its "misleading" and "objectionable" advertisements immediately from the media space.

However, Patanjali spokesperson S K Tijarawala said no such notice has so far been received by the firm.

A similar controversy had erupted when Ramdev had launched Patanjali's "Coronil" tablet in 2021 claiming it to be an evidence-based cure for Covid.

Patanjali is an Indian multinational conglomerate holding company, based in Haridwar, India.

Source : PTI

Ruchika Sharma

M.Com

Ruchika joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751